Patricia LoRusso
Overview
Explore the profile of Patricia LoRusso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
5280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeku O, Barve M, Tan W, Wang J, Patnaik A, LoRusso P, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40081941
Background: Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC....
2.
Luke J, Pinato D, Juric D, LoRusso P, Hosein P, Desai A, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39979069
E7766 is a novel stimulator of interferon genes (STING) agonist, capable of potent activation of immune cells and generating strong antitumor response in preclinical murine tumor models. Here we present...
3.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S, et al.
Front Oncol
. 2025 Feb;
14:1544394.
PMID: 39957803
[This corrects the article DOI: 10.3389/fonc.2024.1376551.].
4.
Champiat S, Garralda E, Galvao V, Cassier P, Gomez-Roca C, Korakis I, et al.
Cell Rep Med
. 2025 Feb;
6(2):101967.
PMID: 39933529
Nanrilkefusp alfa (nanril; SOT101) is an interleukin (IL)-15 receptor βγ superagonist that stimulates natural killer (NK) and CD8 T cells, thereby promoting an innate and adaptive anti-tumor inflammatory microenvironment in...
5.
Harrington K, Kitano S, Gambardella V, Parkes E, Moreno I, Alonso G, et al.
Future Oncol
. 2025 Jan;
21(2):195-200.
PMID: 39817655
BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor...
6.
Lopez J, Powles T, Braiteh F, Siu L, LoRusso P, Friedman C, et al.
Nat Med
. 2025 Jan;
31(1):152-164.
PMID: 39762422
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from...
7.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller K, Kao S, et al.
Front Oncol
. 2024 Nov;
14:1376551.
PMID: 39534099
Background: Transforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface...
8.
Choi Y, Dharia N, Jun T, Chang J, Royer-Joo S, Yau K, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3788-3797.
PMID: 38995268
Purpose: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS...
9.
Hong D, LoRusso P, Sznol M
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 38991727
The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19...
10.
Maldonado E, Rathmell W, Shapiro G, Takebe N, Rodon J, Mahalingam D, et al.
Cancer Res Commun
. 2024 Jun;
4(7):1793-1801.
PMID: 38920407
Significance: WEE1 inhibition with adavosertib monotherapy demonstrated limited clinical activity in patients with SETD2-altered solid tumors despite compelling preclinical data indicating a synthetic lethal effect, which did not translate into...